Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Schmalenberg · SciRah

Researcher profile · Semantic Scholar

H. Schmalenberg

Share profile

H. Schmalenberg — researcher profile on SciRah

h-index: 23
Works: 61
Citations: 5,757

Most-cited papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
S. Al-Batran, N. Homann, C. Pauligk, T. Goetze +53 more
2019The Lancet1,937 citations
Semantic Scholar
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
S. Al-Batran, J. Hartmann, S. Probst, H. Schmalenberg +16 more
2008Journal of Clinical Oncology760 citations
Semantic Scholar
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multice
S. Al-Batran, R. Hofheinz, C. Pauligk, H. Kopp +36 more
2016The Lancet Oncology640 citations Open access
Semantic Scholar
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
H. Oettle, Stefan Post, P. Neuhaus, K. Gellert +16 more
2007Journal of the American Medical Association (JAMA)544 citations
Semantic Scholar
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
S. Al-Batran, N. Homann, C. Pauligk, G. Illerhaus +24 more
2017JAMA Oncology435 citations Open access
Semantic Scholar
Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial
T. Götze, N. Homann, H. Schmalenberg, HG Kopp +25 more
2017Zeitschrift für Gastroenterologie - German Journal of Gastroenterology231 citations
Semantic Scholar
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI
S. Al-Batran, T. Goetze, D. W. Mueller, A. Vogel +37 more
2017BMC Cancer212 citations Open access
Semantic Scholar
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
U. Kaiser, Irmgard Uebelacker, U. Abel, J. Birkmann +25 more
2002Journal of Clinical Oncology145 citations Open access
Semantic Scholar
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer
S. Lorenzen, C. Pauligk, N. Homann, H. Schmalenberg +3 more
2012British Journal of Cancer116 citations Open access
Semantic Scholar
Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
A. Wunderlich, M. Kloess, Marcel Reiser, C. Rudolph +6 more
2003Annals of Oncology98 citations Open access
Semantic Scholar
Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer
J. Inhestern, K. Oertel, V. Stemmann, H. Schmalenberg +9 more
2015PLoS ONE68 citations Open access
Semantic Scholar
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials
A. Wagner, P. Buechner-Steudel, M. Moehler, H. Schmalenberg +7 more
2009British Journal of Cancer62 citations Open access
Semantic Scholar
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharynge
J. Inhestern, H. Schmalenberg, A. Dietz, N. Rotter +8 more
2017Annals of Oncology40 citations Open access
Semantic Scholar
Trends in epidemiology and treatment and outcome for head and neck cancer: a population-based long-term analysis from 1996 to 2011 of the Thuringian cancer registry.
O. Guntinas-Lichius, T. Wendt, Nicole Kornetzky, J. Buentzel +6 more
2014Oral Oncology40 citations
Semantic Scholar
A randomized phase III trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP).
S. Al-Batran, J. T. Hartmann, Stephan Probst, R. Hofheinz +6 more
2006Journal of Clinical Oncology40 citations
Semantic Scholar
Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
O. Schoffer, Stefanie Schülein, Gerlinde Arand, H. Arnholdt +54 more
2016BMC Cancer34 citations Open access
Semantic Scholar
Incidence, treatment, and outcome of parotid carcinoma, 1996–2011: a population-based study in Thuringia, Germany
O. Guntinas-Lichius, T. Wendt, J. Buentzel, D. Esser +6 more
2015Journal of Cancer Research and Clinical Oncology33 citations Open access
Semantic Scholar
The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
S. Al-Batran, C. Pauligk, R. Wirtz, D. Werner +8 more
2012Annals of Oncology29 citations Open access
Semantic Scholar
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion—A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
S. Al-Batran, R. Hofheinz, H. Schmalenberg, D. Strumberg +16 more
202027 citations
Semantic Scholar
Pharmacokinetics of 5-Fluorouracil in Patients Heterozygous for the IVS14+1G > A Mutation in the Dihydropyrimidine Dehydrogenase Gene
A. V. van Kuilenburg, J. Maring, A. Schalhorn, C. Terborg +5 more
2008Nucleosides, Nucleotides & Nucleic Acids26 citations
Semantic Scholar
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM
T. Goetze, R. Hofheinz, T. Gaiser, H. Schmalenberg +19 more
2023International Journal of Cancer25 citations
Semantic Scholar
LBA-008Docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) as perioperative treatment of resectable gastric or gastro-esophageal junction adenocarcinoma: The multicenter, randomized phase 3 FLOT4 trial (German Gastric Gr
S. Al-Batran, C. Pauligk, N. Homann, H. Schmalenberg +14 more
2017Annals of Oncology24 citations Open access
Semantic Scholar
LBA27_PRDocetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO)
S. Al-Batran, C. Pauligk, N. Homann, H. Schmalenberg +16 more
201724 citations Open access
Semantic Scholar
Pathological response to neoadjuvant 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO.
C. Pauligk, A. Tannapfel, J. Meiler, K. Luley +16 more
201523 citations
Semantic Scholar
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
S. Al-Batran, C. Pauligk, R. Hofheinz, S. Lorenzen +12 more
2019Journal of Clinical Oncology20 citations
Semantic Scholar
Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie).
P. Thuss-Patience, S. Al-Batran, J. Siveke, N. Homann +16 more
201518 citations
Semantic Scholar
Cutaneous Langerhans cell histiocytosis with subsequent development of haematological malignancies. Report of two cases.
U. Wollina, M. Kaatz, C. Krönert, J. Schönlebe +4 more
2006Acta Dermatovenerologica Alpina Pannonica et Adriatica17 citations
Semantic Scholar
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
A. Wagner, P. Buechner-Steudel, A. Wein, H. Schmalenberg +6 more
2006Annals of Oncology16 citations Open access
Semantic Scholar
Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
K. Oertel, K. Spiegel, H. Schmalenberg, A. Dietz +5 more
2012BMC Cancer15 citations Open access
Semantic Scholar
First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A—results of a retrospective analysis
M. Pouyiourou, A. Meyer, A. Stroux, A. Viardot +21 more
2020Annals of Hematology14 citations
Semantic Scholar
Prognostic value of tumor volumetry data of routine imaging data in a head and neck cancer registry
Daniela Oemus, J. Inhestern, H. Schmalenberg, S. Schultze-Mosgau +2 more
2014European Archives of Oto-Rhino-Laryngology9 citations
Semantic Scholar
A prospective trial for defining a subset of patients with limited metastatic gastric cancer who may be candidates for bimodal treatment strategies: FLOT3.
S. Al-Batran, R. Hofheinz, N. Homann, G. Illerhaus +17 more
20129 citations
Semantic Scholar
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
T. Thomaidis, A. Maderer, S. Al-Batran, J. Kany +8 more
2014BMC Cancer8 citations Open access
Semantic Scholar
1424MO Perioperative FLOT plus ramucirumab versus FLOT alone for resectable esophagogastric adenocarcinoma– Updated results and subgroup analyses of the randomized phase II/III trial RAMSES/FLOT7 of the German AIO and Italian GOIM
S. Al-Batran, R. Hofheinz, H. Schmalenberg, D. Strumberg +16 more
20206 citations Open access
Semantic Scholar
CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach
H. Schmalenberg, S. Al-Batran, C. Pauligk, T. Zander +13 more
2018Journal of Cancer Research and Clinical Oncology6 citations Open access
Semantic Scholar
Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK.
N. Homann, S. Lorenzen, M. Schenk, P. Thuss-Patience +16 more
20205 citations
Semantic Scholar
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK
S. Al-Batran, C. Pauligk, R. Hofheinz, S. Lorenzen +16 more
2019Annals of Oncology5 citations Open access
Semantic Scholar
Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7) with high rate of signet cell component: Final results of the multicenter, randomized phase II/III trial of the German AIO and Italian GOIM.
T. Goetze, R. Hofheinz, H. Schmalenberg, D. Strumberg +16 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
Defining two prognostic groups of metastatic gastric cancer: FLOT3 trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
S. Al-Batran, R. Hofheinz, N. Homann, Gerald Illerhaus +15 more
2011Journal of Clinical Oncology4 citations
Semantic Scholar
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial
M. Scheck, T. Goetze, T. Ettrich, H. Schmalenberg +15 more
2024Oncology Research and Treatment3 citations Open access
Semantic Scholar
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as a 24-hr-infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: preliminary results of a multicenter phase II-study.
A. Wagner, P. Buechner-Steudel, A. Wein, R. Masri-Zada +6 more
2004Journal of Clinical Oncology3 citations
Semantic Scholar
Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO.
T. Goetze, P. Piso, U. Bankstahl, C. Pauligk +14 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
Tumour stage distribution and survival of malignant melanoma in Germany 2002–2011
O. Schoffer, Stefanie Schülein, Gerlinde Arand, H. Arnholdt +54 more
2016BMC Cancer2 citations Open access
Semantic Scholar
Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study.
C. Pauligk, J. Meiler, R. Hofheinz, H. Kopp +16 more
20132 citations
Semantic Scholar
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO
S. Lorenzen, C. Pauligk, T. Goetze, J. R. Knorrenschild +15 more
2019Annals of Oncology1 citations Open access
Semantic Scholar
PD-L1 mRNA expression in patients with resectable gastric cancer and adenocarcinoma of the oesophago-gastric junction undergoing perioperative chemotherapy: Results from the FLOT4 phase III trial of the AIO.
L. Waberer, N. Homann, R. Wirtz, H. Schmalenberg +7 more
20181 citations
Semantic Scholar
A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST).
H. Schmalenberg, C. Pauligk, T. Zander, Alexander Reichart +13 more
20171 citations
Semantic Scholar
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as a 24-hr-infusion in chemonaive patients with advanced or metastatic carcinoma of the gallbladder: Preliminary results of a multicenter phase II-study.
A. Wagner, P. Buechner-Steudel, H. Schmalenberg, M. Moehler +6 more
2006Journal of Clinical Oncology1 citations
Semantic Scholar
Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase 2 IKF-S627/RAMOS trial of the AIO.
M. Scheck, T. Goetze, T. Ettrich, H. Schmalenberg +14 more
2023Journal of Clinical Oncology0 citations Open access
Semantic Scholar
1535P Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
M. Scheck, T. Goetze, T. Ettrich, H. Schmalenberg +15 more
2023Annals of Oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Pauligk×30
Invite
C. Pauligk — researcher profile on SciRah
N. Homann×26
Invite
N. Homann — researcher profile on SciRah
S. Al-Batran×24
Invite
S. Al-Batran — researcher profile on SciRah
R. Hofheinz×22
Invite
R. Hofheinz — researcher profile on SciRah

×19

Invite

T. Goetze — researcher profile on SciRah

Invite

E. Jäger — researcher profile on SciRah

Invite

H. Kopp — researcher profile on SciRah

Invite

K. Luley — researcher profile on SciRah

Invite

S. Probst — researcher profile on SciRah

Invite

M. Egger — researcher profile on SciRah

Invite

M. Moehler — researcher profile on SciRah

Invite

G. Haag — researcher profile on SciRah